• CSL Behring LLC, of King of Prussia, Pa., said the first patient was screened in its recombinant coagulation single-chain Factor VIII trial in hemophilia A. The study is part of the AFFINITY Phase I/II trial program, which is testing crossover safety, efficacy and pharmacokinetics of the product compared to recombinant human antihemophilic Factor VIII (octocog alpha).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter